Did you finish first line chemo for stage 3 or ... - My Ovacome

My Ovacome

18,141 members20,291 posts

Did you finish first line chemo for stage 3 or 4 ovarian, fallopian tube or primary peritoneal cancer between 14 Sept 2021 and 14 July 2022?

OvacomeSupport profile image
OvacomeSupportPartnerMy Ovacome Team
0 Replies

Good morning all

Have you been diagnosed with stage 3 or 4 ovarian, primary peritoneal or fallopian tube cancer and did you have your last dose of first line chemotherapy sometime between 14 September 2021 and 14 July 2022?

If so, you may be eligible to take part in an important new study which aims to identify areas for improvement in supporting the lives of patients at different stages of their treatment pathway and to contribute to the mutual understanding between patients and their consultants, nurses and surgeons.

As well as looking at the emotional and physical effects felt by patients after treatment, it will investigate whether clinicians understand these challenges and how they might be supported to address the clinical and emotional needs of those they treat.

This study involves completing a survey. This is non-interventional observational study, meaning that participants will not receive any treatment as part of the study.

All study participants will receive £50 on successful completion of the survey.

Here is some further information about criteria for participation:

• You must have received treatment in the UK.

• You must be over 18.

• You must have been diagnosed with epithelial ovarian cancer (high grade serous, low grade serous, endometrioid, clear cell, mucinous), fallopian tube cancer, or primary peritoneal cancer.

• You must have been diagnosed at stage 3 or 4.

• As first line treatment you must have had either:

• Chemotherapy only

• Surgery and then chemotherapy

• Chemotherapy, followed by surgery, followed by more chemotherapy

• You must have finished your first line chemotherapy treatment between two and 12 months prior to taking part in the survey.

If you would like to know more about this study, please visit ovacome.org.uk/news/patron.

If you would like to participate in this study please contact Serena Lavin at the fieldwork agency via 01625 668988 or serena.lavin@defactoresearch.com

To learn more, you can also contact the Ovacome support team on 0800 008 7054 or by emailing support@ovacome.org.uk. Please don’t hesitate to get in touch if we can help with any further information or if there is anything we can do to support your participation.

If you have already completed the study or aren't eligible to participate, it would be much appreciated if you could share details of the study with your clinical teams or any contacts who may be eligible to take part.

Best wishes

Annie - Ovacome support

Written by
OvacomeSupport profile image
OvacomeSupport
Partner
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Niraparib - NICE appraisal

Dear All The National Institute for Health and Care Excellence (NICE) have contacted Ovacome...

Rucaparib submission to NICE

Hello All We are preparing a submission to NICE regarding Rucaparib becoming available on the NHS....

Rucaparib - NICE appraisal

Dear All The National Institute for Health and Care Excellence (NICE) have contacted Ovacome...

My juicing formula for my mother with stage 4 primary peritoneal cancer/ovarian cancer now almost fully recovered

Greetings to all, Just want to share with you the juicing formula I used for my mom to supplement...

Your help needed to promote My Ovacome

Hello All You may have seen my post about this before Christmas, apologies for the repetition but...